First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
The drug will be available in 600 hospitals and 105 DTPs
The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma
The investment will accelerate the overall Sarclisa development program
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
Dr. Shah will lead strategic and operational clinical development of the company's diverse pipeline
Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as the foundation for various investigational CAR-T therapies
Subscribe To Our Newsletter & Stay Updated
